Salmeflo Description

25 mcg/125 mcg MDI: Each actuation delivers: Salmeterol (as xinafoate) 25 mcg, Fluticasone Propionate 125 mcg.
25 mcg/250 mcg MDI: Each actuation delivers: Salmeterol (as xinafoate) 25 mcg, Fluticasone Propionate 250 mcg.
50 mcg/250 mcg DPI: Each dry powder for inhalation capsule contains: Salmeterol (as xinafoate) 50 mcg, Fluticasone propionate 250 mcg.
50 mcg/500 mcg DPI: Each dry powder for inhalation capsule contains: Salmeterol (as xinafoate) 50 mcg, Fluticasone propionate 500 mcg.
MDI: Salmeterol xinafoate is a selective long-acting (12 hours) β2-adrenoreceptor agonist with a long side chain which binds to the exo-site of the receptor. These pharmacological properties of salmeterol offer more effective protection against histamine-induced bronchoconstriction and produce a longer duration of bronchodilation, lasting for at least 12 hours, than recommended doses of conventional short-acting β2-agonists.
Fluticasone propionate given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma, without the adverse effects observed when corticosteroids are administered systemically. Daily output of adrenocortical hormones usually remain within the normal range during chronic treatment with inhaled fluticasone propionate, even at the highest recommended doses in children and adult. After transfer from other inhaled steroids, the daily output gradually improves despite past and present intermittent use of oral steroids, thus demonstrating return of normal adrenal function on inhaled fluticasone propionate. The adrenal reserve also remains normal during chronic treatment, as measured by a normal increment on stimulation test. However any residual impairment of adrenal reserve from the previous treatment may persist for a considerable time and should be borne in mind.